Anxo Pharmaceutical Co (ROCO:6677) Research & Development: NT$131.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6677 Anxo Pharmaceutical Co Ltd ROCO:6677
66 GF Score
Price NT$17.20
GF Value NT$30.26
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Anxo Pharmaceutical Co Research & Development?

Anxo Pharmaceutical Co ROCO:6677 +0.88% 66 Research & Development is NT$131.1 Mil as of Dec. 2025. GuruFocus rates ROCO:6677 with a GF Score™ of 66/100 and a GF Value™ of NT$30.26 (Possible Value Trap). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Anxo Pharmaceutical Co's Research & Development for the six months ended in Dec. 2025 was NT$69.4 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$131.1 Mil.

Anxo Pharmaceutical Co  (ROCO:6677) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Anxo Pharmaceutical Co Research & Development Related Terms

Anxo Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Anxo Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anxo Pharmaceutical Co Research & Development Chart

Anxo Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 111.38 139.59 139.20 148.43 131.11

Anxo Pharmaceutical Co Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 68.44 60.38 88.05 61.74 69.37
ROCO:6677
66GF Score
Anxo Pharmaceutical Co Ltd ROCO:6677
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anxo Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$131.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$131.1 Mil mean?
Anxo Pharmaceutical Co (ROCO:6677) has a Research & Development of NT$131.1 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Anxo Pharmaceutical Co and its competitors.
Is Anxo Pharmaceutical Co's Research & Development too high?
Anxo Pharmaceutical Co's current Research & Development is NT$131.1 Mil. Overall, Anxo Pharmaceutical Co has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Anxo Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Anxo Pharmaceutical Co's Research & Development of NT$131.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Anxo Pharmaceutical Co and its competitors. Anxo Pharmaceutical Co's current Research & Development is NT$131.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anxo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Anxo Pharmaceutical Co (ROCO:6677) is currently considered Possible Value Trap. The stock's GF Value™ is NT$30.26, compared to a current price of NT$17.20 — trading 43.2% below its estimated fair value. The current Research & Development is NT$131.1 Mil. Anxo Pharmaceutical Co's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Anxo Pharmaceutical Co (ROCO:6677), the current Research & Development is NT$131.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anxo Pharmaceutical Co (ROCO:6677) Overvalued in 2026?

Based on GuruFocus' analysis, Anxo Pharmaceutical Co stock appears to be undervalued. The current stock price of NT$17.20 is trading 43.2% below its estimated GF Value™ of NT$30.26. GuruFocus considers Anxo Pharmaceutical Co to be Possible Value Trap.

Key valuation signals for ROCO:6677:

  • Research & Development: NT$131.1 Mil
  • GF Value™: NT$30.26 vs. price of NT$17.20 (43.2% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6677 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anxo Pharmaceutical Co Business Description

Address 8th Floor-3, Nanjing East Road, No. 206, Section 2, Taipei City, TWN
Anxo Pharmaceutical Co Ltd is a drug manufacturer. The company is engaged in developing drugs which include prescription medication and consumer healthcare medication. The products of the company include cardiovascular system medication, central nervous system medication, diabetes medication, infectious medicine, and dermatology medication.
66GF Score

Get the complete analysis for ROCO:6677

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.20
Price
NT$30.26
GF Value